Physician profile
Michael Cain
NPI 1922001627
$7,521.38
in general payments reported to CMS, 2019-2025
55 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $503 · 2021: $977 · 2022: $742 · 2023: $1,263 · 2024: $1,843 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,585.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $860.30 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $632.85 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $606.47 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $554.99 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $544.11 | 2019-2025 | |
| Daiichi Sankyo INC. | $408.12 | 2020-2025 | Enhertu, Injectafer |
| Genzyme Corporation | $404.69 | 2019-2025 | |
| Janssen Biotech, INC. | $297.24 | 2019-2024 | Tecvayli, Darzalex, Carvykti |
| Gilead Sciences, INC. | $293.46 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $224.54 | 2019-2025 | Enhertu, Imfinzi |
| Beigene USA, INC. | $180.38 | 2020-2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $158.16 | 2023-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Kite Pharma, INC. | $154.43 | 2020-2024 | Yescarta |
| Eusa Pharma (US) LLC | $146.50 | 2019-2020 | |
| Astellas Pharma US INC | $119.15 | 2019-2025 | Xtandi |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.